Merck KGaA’s Lipfendra became the first oral PCSK9 inhibitor approved by the FDA for lowering LDL cholesterol in adults with high cholesterol. The approval advances a new delivery approach for PCSK9 inhibition, where class members are typically injectable peptides. Merck described Lipfendra as a macrocyclic peptide engineered for oral formulation, supporting a switch in administration route for patients who may prefer non-injectable therapies. The approval positions the oral option within a rapidly growing cholesterol-lowering landscape. For biotech and pharma, the key development is not only efficacy expectations but also formulation science translating peptide pharmacology into oral dosing. That shift may influence competitive differentiation across peptide and small-molecule modalities. The excerpt does not provide trial names or outcomes, but the headline regulatory milestone is the FDA approval itself for Lipfendra as the class’s first oral therapy.